Pancreatic Neuroendocrine Tumors in the 21st Century � An Update

R Kanthan, JL Senger, S Ahmed and SC Kanthan

Department of Pathology & Laboratory Medicine, University of Saskatchewan, Canada
Department of Surgery, University of Alberta, Canada
Division of Medical Oncology, University of Saskatchewan, Canada
Deparmtent of Surgery, University of Saskatchewan, Canada

^*Correspondance to: Jenna-Lynn Senger 

 PDF  Full Text DOI: 10.25107/2474-1647.1662

Abstract

Pancreatic Neuroendocrine Tumors (PNETs) are rare, reported to account for less than 1-2% of all pancreatic tumors. This, however, is likely an underestimation, as improved radiologic techniques and heightened awareness have resulted in an increase in the detection of incidentalomas, with estimations of true prevalence as high as 10%. The term “PNET” is an umbrella name encompasses a heterogenous group of neoplasms each with distinct clinical presentations, diagnostic radiographic features, management principles, and tumor/patient outcomes. In this context, accurate diagnosis is challenging, and management guidelines unclear. A high degree of clinical suspicion is required for best patient management. This manuscript provides a comprehensive of PNETs in the 21st century, in which we review the terminology, epidemiology classification, aetiopathogenesis, radiographic and histopathologic diagnostic features, management for localized and metastatic disease, as well as a review of features defining functional and non-functional PNETS, and finally describe prognostic features.

Keywords

Pancreatic neuroendocrine tumor; Insulinoma; Gastrinomas

Cite the article

Kanthan R, Senger JL, Ahmed S, Kanthan SC. Pancreatic Neuroendocrine Tumors in the 21st Century � An Update. Clin Surg. 2017; 2: 1662.